Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616928 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
A Phase 3 study of Influenza, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,561
- Enrollment target
- 20
- Study locations
NCT00616928 is a Phase 3 study of Influenza that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,561 participants, below the 36,775-participant average among 156 other Influenza trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00616928, a Phase 3 study of Influenza, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,561 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Study Locations (20)
Florida
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Melbourne
- GSK Investigational Site - Miami
- GSK Investigational Site - Pembroke Pines
Illinois
- GSK Investigational Site - Chicago
- GSK Investigational Site - Peoria
Kansas
- GSK Investigational Site - Lenexa
- GSK Investigational Site - Wichita
Alabama
- GSK Investigational Site - Huntsville
Arizona
- GSK Investigational Site - Phoenix
California
- GSK Investigational Site - Anaheim
Georgia
- GSK Investigational Site - Stockbridge
Indiana
- GSK Investigational Site - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,561 participants |
| Start Date | 2008-01-23 |
| Est. Completion | 2009-03-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616928
The ClinicalTrials.gov registry entry for NCT00616928 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,561 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,775-participant average among 156 other Influenza trials with a reported enrollment target (88% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00616928 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT00616928 about?
NCT00616928 is a clinical study titled "Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years". The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.
What is the current status of trial NCT00616928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,561 participants. The study started on 2008-01-23. Estimated completion is 2009-03-19.
What conditions does trial NCT00616928 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00616928?
The interventions under investigation include: Placebo (BIOLOGICAL), Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (BIOLOGICAL).
Who is sponsoring clinical trial NCT00616928?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616928 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
-
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.